Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check5 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4. This reflects an updated version of the study record, without altering the reported study details.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page footer revision was updated from v3.5.2 to v3.5.3, indicating a minor site/version update without changing the study information presented.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the study details or page functionality.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision updated: v3.4.2 removed; v3.4.3 added.SummaryDifference0.1%

- Check99 days agoChange DetectedAdded site revision tag Revision: v3.4.2 and removed an operating-status notice (lapse in government funding) along with Revision: v3.4.1. The core study details, eligibility criteria, and trial information remain unchanged.SummaryDifference0.5%

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.